SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+58.64%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.79B
AUM Growth
+$1.79B
(+24%)
Cap. Flow
-$228M
Cap. Flow
% of AUM
-12.79%
Top 10 Holdings %
Top 10 Hldgs %
65.35%
Holding
73
New
17
Increased
15
Reduced
16
Closed
9
Top Buys
| 1 |
Eli Lilly
LLY
|
$37.6M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$33.3M |
| 3 |
Kura Oncology
KURA
|
$24M |
| 4 |
Incyte
INCY
|
$18.6M |
| 5 |
Stryker
SYK
|
$17.8M |
Top Sells
| 1 |
Natera
NTRA
|
$97.1M |
| 2 |
DexCom
DXCM
|
$65.8M |
| 3 |
Cytokinetics
CYTK
|
$53.9M |
| 4 |
Elanco Animal Health
ELAN
|
$36M |
| 5 |
AstraZeneca
AZN
|
$34.5M |
Sector Composition
| 1 | Healthcare | 97.37% |
| 2 | Consumer Staples | 1.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $437M | 24.45% | 1,381,149 | – | – |
|
|
RYZB
2
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $150M | 8.41% | 2,419,528 | – | – |
|
|
3
Natera
NTRA
$23.1B
| $97.1M | 5.43% | 1,550,280 -1,550,280 | -50% | -$97.1M |
|
4
Ascendis Pharma
ASND
$11.8B
| $95M | 5.31% | 754,032 | – | – |
|
5
Merck
MRK
$210B
| $93.5M | 5.23% | 857,971 +129,567 | +18% | +$14.1M |
|
|
JBIO
6
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $85.1M | 4.76% | 3,758,686 | – | – |
|
|
7
AstraZeneca
AZN
$248B
| $57.3M | 3.2% | 850,577 -512,259 | -38% | -$34.5M |
|
8
Vera Therapeutics
VERA
$1.38B
| $53.3M | 2.98% | 3,467,156 | – | – |
|
9
IDEAYA Biosciences
IDYA
$2.15B
| $51.9M | 2.9% | 1,458,881 +421,694 | +41% | +$15M |
|
|
IMGN
10
DELISTED
Immunogen Inc
IMGN
| $45.9M | 2.57% | 1,546,902 -498,300 | -24% | -$14.8M |
|
11
Intuitive Surgical
ISRG
$170B
| $42.8M | 2.4% | 126,959 -46,318 | -27% | -$15.6M |
|
|
12
Eli Lilly
LLY
$657B
| $37.6M | 2.1% | +64,525 | New | +$37.6M |
|
|
13
Cytokinetics
CYTK
$4.23B
| $34.6M | 1.93% | 414,207 -645,957 | -61% | -$53.9M |
|
14
Celldex Therapeutics
CLDX
$1.47B
| $33.5M | 1.87% | 844,008 +419,749 | +99% | +$16.6M |
|
|
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
| $33.3M | 1.87% | +1,411,769 | New | +$33.3M |
|
16
Immatics
IMTX
$619M
| $31.3M | 1.75% | 2,969,039 -282,470 | -9% | -$2.97M |
|
17
Sanofi
SNY
$121B
| $29.8M | 1.67% | 598,978 -96,397 | -14% | -$4.79M |
|
|
INBX
18
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $29.4M | 1.64% | 772,957 +29,663 | +4% | +$1.13M |
|
19
Kenvue
KVUE
$39.7B
| $26M | 1.45% | 1,206,939 -595,145 | -33% | -$12.8M |
|
|
20
Kura Oncology
KURA
$686M
| $24M | 1.34% | +1,667,321 | New | +$24M |
|
21
Syndax Pharmaceuticals
SNDX
$1.41B
| $23.2M | 1.3% | 1,075,786 +133,969 | +14% | +$2.9M |
|
|
MRNS
22
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $19.3M | 1.08% | 1,772,699 +787,093 | +80% | +$8.56M |
|
|
23
Stryker
SYK
$150B
| $18.8M | 1.05% | 62,788 +59,509 | +1,815% | +$17.8M |
|
|
24
Incyte
INCY
$16.5B
| $18.6M | 1.04% | +296,569 | New | +$18.6M |
|
25
Geron
GERN
$893M
| $18.6M | 1.04% | 8,814,497 +5,111,951 | +138% | +$10.8M |
|